secwatch.observer — SEC 8-K summary
======================================

Issuer:     GRI Bio, Inc. (GRI)
CIK:        0001824293
Form:       8-K
Filed at:   2026-02-04T23:59:59+00:00
Accession:  0001824293-26-000040
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GRI Bio reiterates FY2025 results: $8.2M cash, $12M loss; raises $6.5M, runway into Q1 2027
--------------------------------------------------------------------------------

- Cash and cash equivalents of $8.2M at Dec 31, 2025; raised additional $6.5M in Jan 2026 via ATM offering.
- Net loss for FY2025 was $12M; R&D expenses increased to $6.8M from $3.8M year-over-year.
- Cash runway expected to fund planned operations into the first quarter of 2027.
- Positive Phase 2a data for GRI-0621 in idiopathic pulmonary fibrosis reinforces clinical proof-of-concept.
- Advancing GRI-0803 for autoimmune indications through IND-enabling studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824293/000182429326000040/0001824293-26-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824293/000182429326000040/val-20260204.htm
  HTML page:      https://secwatch.observer/filing/0001824293-26-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer